Skip to main content
Coagulation Disorders on Muck Rack

Coagulation Disorders

As seen in: Oxford University Press (OUP), JAMA Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Coagulation

Contact Coagulation, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcome of patients supported with the HeartMate 3 after extracorporeal life support: On behalf of the Durable Mechanical Circulatory Support After Extracorporeal Life Support Study Group

|
By Diyar Saeed, Coagulation Disorders, Wolfgang Otto, Christoffer Stark
| uke.de
OBJECTIVES: The Durable Mechanical Circulatory Support System After Extracorporeal Life Support registry is a multicenter registry of patients who were bridged from extracorporeal life support to a durable mechanical circulatory support system. Although numerous studies have highlighted the favorable outcomes after implantation of the HeartMate 3 (Abbott), the objective of our study is to examine the outcomes of patients who received HeartMate 3 support after extracorporeal life support.
Open in Who Shared Issue with article?

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma

|
By Elin Edda Sigurdardottir, Coagulation Disorders, Sigurdur Y. Kristinsson
| JAMA (The Journal of the American Medical Association) Verified
Importance  Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.
Open in Who Shared Issue with article?

Second primary malignancies in multiple myeloma: an overview and IMWG consensus

|
By New Brunswick, Hematologic Oncology, Hôpital Antoine, Coagulation Disorders
| Oxford University Press (OUP)
The potential for patients originally diagnosed with multiple myeloma (MM) to develop solid or hematologic second primary malignancies (SPMs) has long been recognized. Forty-five years ago, Dr Robert Kyle and co-workers described the subsequent development of acute myeloid leukemia (AML) in four patients who had received prolonged melphalan treatment for MM or systemic amyloidosis [1].
Open in Who Shared Issue with article?
See all 3 articles